Prostate Cancer
What's New
Last Posted: Jun 27, 2024
- Screening guidelines for people at increased risk for prostate cancer.
Justin Lorentz et al. Can Urol Assoc J 2024 - Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage.
Michael S Leapman et al. JAMA Netw Open 2024 7(6) e2417274 - The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
Elizabeth K Bancroft et al. BJU Int 2024 - Development and validation of a machine learning model for bone metastasis in prostate cancer: Based on inflammatory and nutritional indicators.
Tongtong Jin et al. Urology 2024 - Utilization of A Third-Party Partnership in Tele-genetic Risk Assessment Program in Genitourinary Oncology.
Lin Lin et al. Urology 2024 - Catalyzing Precision Medicine: Artificial Intelligence Advancements in Prostate Cancer Diagnosis and Management.
Ali Talyshinskii et al. Cancers (Basel) 2024 16(10) - The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review
- Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches.
Ray Manneh et al. JCO Precis Oncol 2024 8e2300628 - Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives.
Michiel Vlaming et al. Fam Cancer 2024 - Outcomes of a universal germline screening program in a community urology practice.
Neil Mendhiratta et al. Clin Genet 2024 - Trial of Electronic Medical Record Integrated Next-Generation Sequencing Ordering in Veterans Affairs Cancer Care.
James H Stoeckle et al. JCO Precis Oncol 2024 8e2300463 - Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score® (GPS) assay.
Amy M Nguyen et al. Prostate 2024 - Predictive value of magnetic resonance imaging diffusion parameters using artificial intelligence in low-and intermediate-risk prostate cancer patients treated with stereotactic ablative radiotherapy: A pilot study.
A Kedves et al. Radiography (Lond) 2024 30(3) 986-994 - Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
- Clinical features of prostate cancer by polygenic risk score.
Christina Spears et al. Fam Cancer 2024 - Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
Florian Rumpf et al. J Urol 2024 101097JU0000000000003927 - Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary-Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis.
Susan Prendeville et al. Mod Pathol 2024 100489 - Explainable and visualizable machine learning models to predict biochemical recurrence of prostate cancer.
Wenhao Lu et al. Clin Transl Oncol 2024 - Men's sociotechnical imaginaries of artificial intelligence for prostate cancer diagnostics - A focus group study.
Emilie Hybertsen Lysø et al. Soc Sci Med 2024 347116771 - Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX.
Eugenio Bologna et al. Clin Pract 2024 14(2) 508-520 - Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
Xin Wang et al. Clin Genitourin Cancer 2024 102052 - TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
Stacy Loeb et al. JCO Precis Oncol 2024 8e2300552 - The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Srinivas Teppala et al. Int J Technol Assess Health Care 2024 40(1) e14 - Development and Validation of a Deep Learning Model to Reduce the Interference of Rectal Artifacts in MRI-based Prostate Cancer Diagnosis.
Lei Hu et al. Radiol Artif Intell 2024 e230362 - Machine learning prediction of Gleason grade group upgrade between in-bore biopsy and radical prostatectomy pathology.
Kaan Ozbozduman et al. Sci Rep 2024 14(1) 5849 - Prediction of clinically significant prostate cancer using radiomics models in real-world clinical practice: a retrospective multicenter study.
Jie Bao et al. Insights Imaging 2024 15(1) 68 - Highly accurate and effective deep neural networks in pathological diagnosis of prostate cancer.
Chengwei Zhang et al. World J Urol 2024 42(1) 93 - Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
Arnab Basu et al. J Natl Cancer Inst 2024 2 - Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand.
Chalermkiat Kansuttiviwat et al. NPJ Genom Med 2024 9(1) 9 - Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
Adalgisa Guerra et al. Cancer Imaging 2024 24(1) 24
More
About Cancer PHGKB
Cancer PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to cancer...more
Content Summary
Common Type
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: